Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 5/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973950 | 1.00 | AKR1C3 (0.43) | AKR1C3HTTTBXAS1RARBRARG | |
| SCHEMBL379474 | 0.75 | AKR1C3 (0.50) | AKR1C3TBXAS1RXRARXRBRXRG | |
| SCHEMBL1432882 | 0.75 | AKR1C3 (0.38) | AKR1C3TBXAS1RARBRARGRXRA | |
| SCHEMBL8416371 | 0.75 | TUBB4A (0.42) | AKR1C3TBXAS1APEX1 | |
| SCHEMBL379475 | 0.75 | AKR1C3 (0.50) | AKR1C3TBXAS1RXRARXRBRXRG | |
| SCHEMBL12919403 | 0.74 | GLA (0.40) | HTTMAPT | |
| SCHEMBL346857 | 0.72 | — | — | |
| SCHEMBL972621 | 0.72 | KDM4E (0.52) | HTTMAPT | |
| SCHEMBL3400374 | 0.71 | HCAR2 (0.46) | AKR1C3APEX1MAPT | |
| SCHEMBL3400369 | 0.71 | HCAR2 (0.46) | AKR1C3APEX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015240-A1 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, TAS1R1, VAPA | AKR1C3 2573/4885HTT 372/4885TBXAS1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.